oYo-Link® DM1 Antibody Labeling Kit - Labels 100ug

Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002 Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Read more
€0.00 (tax incl.)
Reference:
AT7002-100
Product Details
AT7002-100

Data sheet

Size
Labels 100ug of antibody
Conjugation
DM1
Application
Cell Killing Assays; Cytotoxicity assays
URL - Product
https://alphathera.com/s/oYo-LinkDM1_ProductSpecSheet_V1November2021.pdf

Menu

Settings